A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant

A pioneer experience in Malaysia on In-house Radio-labelling of 131I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose 131I-rituximab-BEAM conditioning autologous transplant

Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – 90Y-ibritumomab tiuxetan is expensive and 131I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labell...

Full description

Bibliographic Details
Main Authors: Jew, Win Kuan, Chiong, Soon Law, Xiang, Qi Wong, Ching, Tiong Ko, Zool, Hilmi Awang, Lee, Ping Chew, Kian-Meng, Chang
Format: Article
Language:English
Published: Elsevier Ltd. 2016
Subjects:
RM Therapeutics. Pharmacology
Online Access:http://ir.unimas.my/id/eprint/12763/
http://ir.unimas.my/id/eprint/12763/1/A%20pioneerexperienceinMalaysiaonIn-houseRadio-labelling%28abstract%29.pdf

Internet

http://ir.unimas.my/id/eprint/12763/
http://ir.unimas.my/id/eprint/12763/1/A%20pioneerexperienceinMalaysiaonIn-houseRadio-labelling%28abstract%29.pdf

Similar Items